![]() ![]() “Despite tremendous progress in our scientific understanding, there remain many cancers where treatments and patient outcomes remain very limited. ![]() What inspires you to work in the science sector and particularly in oncology? Their new drug therapy aims to induce lasting tumour regression by targeting cancer progenitor cells that are responsible for drug resistance, relapse and cancer spread (metastasis) in high-risk disease. Luke Piggott, Chief Scientific Officer, and Jim Tripp, Founder and Principal, at TnA Therapeutics. They began work on an emerging drug target known as Bcl3 and teamed up with Dr. Professor Richard Clarkson, Professor Andrew Westwell, Professor Andrea Brancale and Dr Ellie Rad are a group of Cardiff University academics with wide-ranging interests in cancer drug discovery and biology. As academics moving into the commercial world our ability to benefit from so much leading expertise is very exciting.” “The enthusiasm of the Oncology Development Programme team has been infectious. What are you enjoying about the programme so far? ![]() ![]() Excitingly, the compounds and drug targets they have discovered may also be used to treat other more common cancers. The Alderley Park Oncology Development Programme is working with companies and academic researchers across the UK, to help them develop their innovations more quickly and efficiently, ready to take on new funding or collaborators to accelerate the progress of their innovations commercially.įive months into the programme, and now approaching the end of part one of the Development Phase, we’re taking a look at the eight projects who have impressed the consortium of experts and have made it through.Įstablished by Professor Andrea Brancale, Dr Ramsay McFarlane and Dr Jane Wakeman from Bangor University and Cardiff University, the team have identified unique features of a rare bone cancer called chordoma - subsequently enabling them to identify a series of molecules that inhibit the ability of the cancerous cells to progress the disease. That’s why at Bruntwood SciTech, we teamed up with some of the biggest names in UK cancer research and clinical excellence, plus four major global pharmaceutical and healthcare companies to combine forces and help accelerate the translation of emerging cancer research into patient benefits. Yet according to the World Health Organisation, cancer accounted for nearly 10 million deaths, globally, in 2020 alone.įrom prevention and early diagnosis, to treatment and cancer management, innovation and collaboration sit at the heart of accelerating oncology research. Imagine the day when all cancers can be cured - it’s the ultimate objective of cancer research. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
June 2023
Categories |